Kodiak Sciences Reports Strong KSI-101 APEX Study Results in Macular Edema
Reuters
Nov 05, 2025
Kodiak Sciences Reports Strong KSI-101 APEX Study Results in Macular Edema
Kodiak Sciences Inc. has announced follow-up data from the APEX study evaluating KSI-101 in patients with macular edema secondary to inflammation (MESI). The results demonstrate that ≥90% of patients in the top two dose levels (5 mg and 10 mg) achieved and sustained absence of intraretinal and subretinal fluid through week 20. More than half of the patients experienced a gain of 15 or more letters in best corrected visual acuity (BCVA) by week 20. The top two dose levels have been advanced into the Phase 3 PEAK and PINNACLE studies, which are currently enrolling patients at a faster-than-expected pace. The complete study results, including week 24 data, are scheduled to be presented by Dr. Sumit Sharma at the Angiogenesis, Exudation, and Degeneration 2026 Annual Meeting on February 7, 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF16119) on November 05, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.